Clinical Trial Update: Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating immunization with 8 peptides plus CpG 7909 or Montanide ISA51 in metastatic cutaneous melanoma; study status terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Malignant Melanoma

Drugs mentioned

• CPG 7909 (CpG 7909)
• Montanide ISA51 (adjuvant Montanide ISA51)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-04-07